Cargando…

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDE...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066993/
https://www.ncbi.nlm.nih.gov/pubmed/37005697
http://dx.doi.org/10.1186/s13045-023-01423-7
_version_ 1785018370394947584
author Marchesi, Francesco
Salmanton-García, Jon
Buquicchio, Caterina
Itri, Federico
Besson, Caroline
Dávila-Valls, Julio
Martín-Pérez, Sonia
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Sciume, Mariarita
Labrador, Jorge
Cordoba, Raul
López-García, Alberto
Fracchiolla, Nicola S.
Farina, Francesca
Ammatuna, Emanuele
Cingolani, Antonella
García-Bordallo, Daniel
Gräfe, Stefanie K.
Bilgin, Yavuz M.
Dargenio, Michelina
González-López, Tomás José
Guidetti, Anna
Lahmer, Tobias
Lavilla-Rubira, Esperanza
Méndez, Gustavo-Adolfo
Prezioso, Lucia
Schönlein, Martin
Van Doesum, Jaap
Wolf, Dominik
Hersby, Ditte Stampe
Magyari, Ferenc
Van Praet, Jens
Petzer, Verena
Tascini, Carlo
Falces-Romero, Iker
Glenthøj, Andreas
Cornely, Oliver A.
Pagano, Livio
author_facet Marchesi, Francesco
Salmanton-García, Jon
Buquicchio, Caterina
Itri, Federico
Besson, Caroline
Dávila-Valls, Julio
Martín-Pérez, Sonia
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Sciume, Mariarita
Labrador, Jorge
Cordoba, Raul
López-García, Alberto
Fracchiolla, Nicola S.
Farina, Francesca
Ammatuna, Emanuele
Cingolani, Antonella
García-Bordallo, Daniel
Gräfe, Stefanie K.
Bilgin, Yavuz M.
Dargenio, Michelina
González-López, Tomás José
Guidetti, Anna
Lahmer, Tobias
Lavilla-Rubira, Esperanza
Méndez, Gustavo-Adolfo
Prezioso, Lucia
Schönlein, Martin
Van Doesum, Jaap
Wolf, Dominik
Hersby, Ditte Stampe
Magyari, Ferenc
Van Praet, Jens
Petzer, Verena
Tascini, Carlo
Falces-Romero, Iker
Glenthøj, Andreas
Cornely, Oliver A.
Pagano, Livio
author_sort Marchesi, Francesco
collection PubMed
description Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.
format Online
Article
Text
id pubmed-10066993
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100669932023-04-03 Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry Marchesi, Francesco Salmanton-García, Jon Buquicchio, Caterina Itri, Federico Besson, Caroline Dávila-Valls, Julio Martín-Pérez, Sonia Fianchi, Luana Rahimli, Laman Tarantini, Giuseppe Grifoni, Federica Irene Sciume, Mariarita Labrador, Jorge Cordoba, Raul López-García, Alberto Fracchiolla, Nicola S. Farina, Francesca Ammatuna, Emanuele Cingolani, Antonella García-Bordallo, Daniel Gräfe, Stefanie K. Bilgin, Yavuz M. Dargenio, Michelina González-López, Tomás José Guidetti, Anna Lahmer, Tobias Lavilla-Rubira, Esperanza Méndez, Gustavo-Adolfo Prezioso, Lucia Schönlein, Martin Van Doesum, Jaap Wolf, Dominik Hersby, Ditte Stampe Magyari, Ferenc Van Praet, Jens Petzer, Verena Tascini, Carlo Falces-Romero, Iker Glenthøj, Andreas Cornely, Oliver A. Pagano, Livio J Hematol Oncol Correspondence Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients. BioMed Central 2023-04-01 /pmc/articles/PMC10066993/ /pubmed/37005697 http://dx.doi.org/10.1186/s13045-023-01423-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Marchesi, Francesco
Salmanton-García, Jon
Buquicchio, Caterina
Itri, Federico
Besson, Caroline
Dávila-Valls, Julio
Martín-Pérez, Sonia
Fianchi, Luana
Rahimli, Laman
Tarantini, Giuseppe
Grifoni, Federica Irene
Sciume, Mariarita
Labrador, Jorge
Cordoba, Raul
López-García, Alberto
Fracchiolla, Nicola S.
Farina, Francesca
Ammatuna, Emanuele
Cingolani, Antonella
García-Bordallo, Daniel
Gräfe, Stefanie K.
Bilgin, Yavuz M.
Dargenio, Michelina
González-López, Tomás José
Guidetti, Anna
Lahmer, Tobias
Lavilla-Rubira, Esperanza
Méndez, Gustavo-Adolfo
Prezioso, Lucia
Schönlein, Martin
Van Doesum, Jaap
Wolf, Dominik
Hersby, Ditte Stampe
Magyari, Ferenc
Van Praet, Jens
Petzer, Verena
Tascini, Carlo
Falces-Romero, Iker
Glenthøj, Andreas
Cornely, Oliver A.
Pagano, Livio
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title_full Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title_fullStr Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title_full_unstemmed Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title_short Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
title_sort passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and covid-19: matched-paired analysis in the epicovideha registry
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066993/
https://www.ncbi.nlm.nih.gov/pubmed/37005697
http://dx.doi.org/10.1186/s13045-023-01423-7
work_keys_str_mv AT marchesifrancesco passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT salmantongarciajon passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT buquicchiocaterina passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT itrifederico passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT bessoncaroline passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT davilavallsjulio passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT martinperezsonia passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT fianchiluana passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT rahimlilaman passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT tarantinigiuseppe passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT grifonifedericairene passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT sciumemariarita passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT labradorjorge passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT cordobaraul passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT lopezgarciaalberto passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT fracchiollanicolas passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT farinafrancesca passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT ammatunaemanuele passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT cingolaniantonella passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT garciabordallodaniel passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT grafestefaniek passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT bilginyavuzm passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT dargeniomichelina passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT gonzalezlopeztomasjose passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT guidettianna passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT lahmertobias passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT lavillarubiraesperanza passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT mendezgustavoadolfo passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT preziosolucia passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT schonleinmartin passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT vandoesumjaap passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT wolfdominik passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT hersbydittestampe passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT magyariferenc passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT vanpraetjens passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT petzerverena passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT tascinicarlo passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT falcesromeroiker passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT glenthøjandreas passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT cornelyolivera passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry
AT paganolivio passivepreexposureimmunizationbytixagevimabcilgavimabinpatientswithhematologicalmalignancyandcovid19matchedpairedanalysisintheepicovideharegistry